Shaking Palsy of the Larynx – a Potential Biomarker for Multiple System Atrophy
Objective: To define a clinical biomarker that allows for early identification of Multiple System Atrophy. Background: In its early stages MSA can be difficult to…Analysis of brain-derived blood exosomes for diagnostics of synucleinopathies
Objective: Here, we aimed to determine if measuring of α-synuclein concentration in these vesicles from oligodendrocytes and neurons can distinguish between patients with MSA or…Early synaptic loss and synaptic instability in a mouse model of prodromal Parkinson’s disease
Objective: In order to elucidate very early pathologis of Parkinson’s disease (PD), we focused on synaptic pathologies in a newly developed mouse model of prodromal…A founder French-Canadian GBA mutation, p.W378G, as a cause for synucleinopathies and Gaucher disease
Objective: To examine and characterize founder GBA mutations in the French-Canadian (FC) population Background: GBA mutations are the most common genetic risk factors for Parkinson’s…Temporal evolution of biomarkers from healthy ageing, isolated REM sleep behavior to early Parkinson’s disease
Objective: To study the temporal evolution of biomarkers of various modalities in healthy ageing controls (HC), the prodromal condition of isolated REM sleep behavior disorder…GBA haploinsufficiency accelerated alpha synuclein pathology with altered lipid metabolism in a premotor model of Parkinson’s disease
Objective: To make Parkinson’s disease (PD) mice model and investigate the mechanism how glucocerebrosidase (gba) heterozygous mutations contribute to asyn pathology and development of PD.…Natural occurring antibodies reduce aggregation of α-synuclein
Objective: We tested naturally occurring antibodies (nAbs) against α-synuclein both in vitro as well as in HEK293T cells to determine binding, cell viability and capacity…Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system
Objective: To establish a new combination screening system consisted of high-throughput in vitro assay with phenotype-based in vivo assay and to develop anti-amyloid drugs truly…Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona
Objective: Determine prevalence of REM Sleep Behavior Disorder (RBD) in Sun City, Arizona Background: RBD is the strongest known clinical risk factor for neurodegenerative disorders…Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis
Objective: Determine sensitivity, specificity and predictive value of clinician diagnosed probable REM sleep behavior disorder (PRBD) in predicting alpha-synuclein pathology. Background: Inability to accurately diagnose…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 17
- Next Page »